Treatment of Sinonasal Teratocarcinosarcoma: A Systematic Review and Survival Analysis.

CONCLUSION: Two-year survival rates for SNTCS are 55%. Multimodality treatment outcomes appear to be superior to surgery alone based on the published data of this rare skull base tumor, although heterogeneity of treatment methods and reporting bias limits the generalizability of these findings. PMID: 32954838 [PubMed - as supplied by publisher]
Source: American Journal of Rhinology and Allergy - Category: ENT & OMF Authors: Tags: Am J Rhinol Allergy Source Type: research